News

News Archive

  • 10.29.2023  |  What’s the Superbug Worst Case Scenario? We Ask a Scientist About Antibiotic Resistance

    DOUBLE TALK. | What exactly is antibiotic resistance? To address these questions, and to learn if there are are any potential solutions—or at least ways we can protect ourselves—we’re talking to Dr. Erin Duffy. Dr. Duffy is the Chief of Research and Development at CARB-X, a global nonprofit partnership focused on supporting the development of new antibacterial products.

    Full Story

  • 09.26.2023  |  The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

    THE WALL STREET JOURNAL | New drugs to defeat ‘superbug’ bacteria aren’t reaching patients. The push for antibiotics to fight fast-evolving superbugs is snagging on a broken business model.

    Full Story

  • 08.27.2023  |  Superbugs: why it’s so hard to stop the ‘silent pandemic’

    FINANCIAL TIMES | Antimicrobial resistance already kills millions and is
    projected to get worse. But there is little incentive for Big
    Pharma to tackle the issue.

    Full Story

  • 08.23.2023  |  CARB-X Receives Global Funding in Fight Against Antimicrobial Resistance

    THE RECORD | New, multi-million dollar grants come from the British, German, and Canadian governments.

    Full Story

  • 07.28.2023  |  GARDP and Bugworks join forces to accelerate development of a novel antibiotic to treat serious bacterial infections

    GARDP | GARDP and Bugworks Research Inc., an innovative clinical-stage biopharmaceutical company with research and development facilities in Bangalore, India, to accelerate the development of a new broad-spectrum antibiotic compound aimed at treating serious infections caused by multidrug-resistant bacteria.  

    Full Story

  • 05.15.2023  |  New WHO report highlights progress, but also remaining gaps, in ensuring a robust pipeline of antibiotic treatments to combat antimicrobial resistance (AMR)

    WHO | AMR was associated with nearly 5 million deaths in 2019, however the R&D pipeline for new antibiotics is thin and access to new and existing treatments remains a challenge.

    Full Story

  • 05.07.2023  |  Towards a reformed R&D ecosystem for infectious disease

    WELLCOME | Antimicrobial resistance (AMR) R&D work inside the Bugworks’ facility in Bangalore, India.

    Full Story

  • 03.30.2023  |  Rapid Pathogen ID/AST Market Begins to Recover Post-COVID as Drug-Resistant Infections Spike

    GENOME WEB | After pandemic-related setbacks, makers of rapid pathogen identification (ID) and antimicrobial susceptibility testing (AST) systems foresee a growing crisis of drug-resistant infections moving the needle on adoption of novel diagnostic approaches.

    Full Story

  • 03.29.2023  |  We’re Running Out of New Antibiotics, WHO Warns

    GIZMODO | Experts with the World Health Organization have issued a dire warning about our never-ending battle against dangerous bacteria: The pipeline of new antibiotics, particularly those that can handle drug-resistant bacteria, is running dry. Only around two dozen candidates meant to treat important infections are currently thought to be in clinical trials, with even fewer potential drugs that can reliably take on superbugs in development.

    Full Story

  • 03.28.2023  |  A New Drug-Resistant Fungus Is Spreading in Hospitals. Is It The Last of Us in Real Life?

    THE BRINK | Candida auris isn’t going to “cause a zombie apocalypse tomorrow,” says CARB-X director Kevin Outterson—but researchers do need to take it seriously

    Full Story

  • 03.01.2023  |  NBC NEWS | CDC warns about the rise in almost untreatable Shigella bacterial infections

    The drug-resistant stomach bug, a major cause of inflammatory diarrhea, is a “serious public health threat.”

    Full Story

  • 02.22.2023  |  As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers’ Interest

    JAMA | During the COVID-19 pandemic, antibiotic-resistant infections increased significantly, leading physicians to seek alternative treatments such as phage therapy, a century-old method that uses viruses to selectively kill bacteria. Despite its controversial history and the rise of antibiotics, phage therapy is gaining attention as a potential solution to the growing problem of antibiotic resistance.

    Full Story

  • 01.19.2023  |  Interview with Dr. Su Chiang from CARB-X, a global antibiotic innovation accelerator

    ANTIBIOTIC RESISTANCE AWARENESS PODCAST | Host Ethan Rhee has a special guest to kick off Season 2. Dr. Su Chiang is a Senior Alliance Manager at CARB-X, a global non-profit antibiotic innovation accelerator.

    Full Story

  • 01.16.2023  |  Lumen Bio: ‘We face 2023 with tremendous optimism’

    BIOPHARMA REPORTER | Lumen Bioscience has been highlighting recent progress made on its clinical and regulatory journey while also announcing several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases.

    Full Story